首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence

【2h】

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence

机译：基于现实世界的临床证据评估固定比率联合地格曲格胰岛素/利拉鲁肽（IDegLira）治疗西班牙2型糖尿病的长期成本效益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimTo evaluate the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus comparator regimens for type 2 diabetes in Spain, based on real‐world evidence.

机译：目的根据现实证据评估西班牙固定比例联合地格列克胰岛素/利拉鲁肽（IDegLira）与比较方案治疗2型糖尿病的长期成本效果。

著录项

期刊名称 Wiley-Blackwell Online Open
作者
Pedro Mezquita Raya; Francisco Javier Ampudia Blasco; Barnaby Hunt; Virginia Martin; Brian Larsen Thorsted; Amaury Basse; Hermione Price;
展开▼
作者单位

展开▼
年(卷),期 -1(21),6
年度 -1
页码 1349–1356
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
cost cost‐effectiveness IDegLira insulin real‐world evidence Spain type 2 diabetes;

机译：成本;成本效益;IDegLira;胰岛素;真实证据;西班牙;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence [J] . Raya Pedro Mezquita, Blasco Francisco Javier Ampudia, Hunt Barnaby, Diabetes, obesity & metabolism . 2019,第6期

机译：根据现实世界临床证据评估西班牙2型糖尿病的定义组合胰岛素Degludec / Liraglutide（IDEGLIRA）的长期成本效益
2. The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting [J] . Drummond Russell, Malkin Samuel, Du Preez Michelle, Diabetes, obesity & metabolism . 2018,第10期

机译：2型糖尿病患者的糖尿病患者组合胰岛素Degludec / Liraglutide（IDEGLIRA）与基础推注疗法（胰岛素冰柱U100加胰岛素Aspart）：英国环境中的短期成本效益分析
3. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐na?ve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [J] . Kaku Kohei, Araki Eiichi, Tanizawa Yukio, Diabetes, obesity & metabolism . 2019,第12期

机译：与胰岛素Degludec和Liragludec和Liraglutide在胰岛素-Na've的胰岛素Degludec和Liraglutide中的胰岛素-Na've日本患者的胰岛素Degludec和Liraglutide的卓越疗效卓越的疗效与第3型糖尿病患者，开放标签，随机试验
4. Modeling the variability of insulin sensitivity for people with Type 1 Diabetes based on clinical data from an artificial pancreas study * [C] . R. Blanc, H. M. Romero Ugalde, P.-Y. Benhamou, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2019

机译：根据来自人工胰腺研究的临床数据，对1型糖尿病患者的胰岛素敏感性变异性进行建模*
5. Evaluating Hypoglycemic Risk of Two Basal Insulin Delivery Methods for Type 1 Diabetes: A Comparison of Tresiba Insulin Against Continuous Subcutaneous Insulin Infusion Using Data from Continuous Glucose Monitors [D] . Lane, Benjamin. 2020

机译：评估1型糖尿病两种基础胰岛素递送方法的低血糖风险：使用来自连续葡萄糖监测器的数据进行TRESIBA胰岛素对连续皮下胰岛素输注的比较
6. The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): A short‐term cost‐effectiveness analysis in the UK setting [O] . Russell Drummond, Samuel Malkin, Michelle Du Preez, -1

机译：固定比例联合地格曲胰岛素/利拉鲁肽（IDegLira）与基础推注疗法（甘精胰岛素U100加门冬胰岛素）联合治疗2型糖尿病：英国环境中的短期成本-效果分析
7. Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial [O] . Kohei Kaku, Eiichi Araki, Yukio Tanizawa, 2019

机译：与胰岛素Degludec和Liraglutide（IDEGLIRA）的胰岛素Degludec和Liraglutide在胰岛素-Naïve日本患者中的胰岛素Degludec和Liraglutide中的胰岛素-Naïve，在第3型糖尿病中，开放标签，随机试验

Evaluating the long‐term cost‐effectiveness of fixed‐ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real‐world clinical evidence

摘要

著录项

相似文献

相关主题

期刊订阅